هذه المادة حاصلة على موافقة هيئة الدواء المصرية برقم HF0327OA1751/ 022024 تاريخ الانتهاء 08/02/2026 برجاء إبلاغ الإدارة العامة لتنظيم مواد التسويق والإعلان عن أي مواد دعائية أو تعليمية أو توعوية مخالفة لا تحتوي على هذه البيانات من خلال خدمة الإبلاغ عن مواد دعائية دوائية غير ملائمة www.edaegypt.gov.eg
Active Ingredients: Montelukast Sodium
Action: Selective Leukotrienes receptor antagonist
Indications:
- Indicated in the treatment of asthma as add-on therapy in those 6 months to 5 years old patients and older with mild to moderate persistent asthma who areinadequately controlled on inhaled corticosteroids and in whom “as-needed” short acting beta agonists provide inadequate clinical control of asthma,
- Indicated in the prophylaxis of asthma from 2 years of age and older in which the predominant component is exercise-induced bronchoconstriction.
- May also be an alternative treatment option to low dose inhaled corticosteroids for 2 to 5 years old patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids.